An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response.

We observed a notable trend in patients deriving benefit being more likely to be previously treated with ICI (100% vs. 57.1%, p = 0.24) and more likely to have a matched genomic finding that would suggest benefit (67% vs. 0%, p = 0.11); however, the small number of patients in each group precluded meaningful statistical comparisons. 4 DISCUSSION In this study, we report our institutional treatment outcomes of patients with advanced MCC treated with targeted therapy.

also in 2,380 other papers

When evaluating clinical benefit from pazopanib specifically, we did observe an interesting trend toward benefiting patients being more heavily pretreated, more likely to be treated with prior ICI, and more likely to have a matched genomic feature that might suggest a response.

also in 1,783 other papers